Learn about global shift towards New Approach Methodologies and how organ-on-a-chip models can move beyond innovation into regulatory-grade application and why standardized biology is the missing link.

Learn about gut-on-a-chip model in the OrganoPlate™ platform, used as a screening tool for probiotics and live biotherapeutics with homeostatic and immunomodulatory properties.

Learn how advanced organoid technology and cutting-edge readout platforms can transform preclinical evaluation of intestinal toxicity and drug metabolism.

Explore how our lung models are transforming respiratory research and high-throughput drug testing, with a focus on our newest model, integrating unidirectional flow, perfusable microvascular networks and differentiated airway epithelium.

Discover how human-relevant 3D in vitro models are advancing renal research and accelerating the development of novel, targeted therapies for diseases such as CKD.

Learn how complex 3D in vitro models are redefining cancer research and drug discovery with human-relevant insights for the study of small molecules, antibodies and CAR T-cell therapies.

Learn about our blood-brain barrier disease modeling capabilities.

Explore cutting-edge approaches to modeling the disease progression of MASH and evaluating the efficacy and toxicity of novel treatments in the context of related disease comorbidities such as obesity and weight loss.

Discover how perfusable organoids derived from adult stem cells improve the physiological relevance of intestinal toxicity studies.

Learn how comprehensive in vitro inflammation models are pivotal in improving drug discovery and establishing more effective treatments for patients. The webinar will explore, among other topics, the immuno-suppressive and stimulatory nature of the macrophages in Inflammatory Bowel Disease (IBD).

Dive deep into MIMETAS’ expertise in disease modeling and drug screening within the field of immuno-oncology. The webinar explores, among other topics, the immuno-suppressive and stimulatory nature of the tumor microenvironment (TME) in hepatocellular carcinoma.

Learn how this model has the potential to be utilized as a tool to predict neurotoxic effects of novel ADCs to enable safety predictions at early stages in the development process.

Watch our on-demand webinar and join our speakers Thomas Olivier (MIMETAS) and Rouven Schoppmeyer, PhD (Nikon BioImaging Lab), as they present an overview of the benefits and hurdles of the latest imaging techniques utilized in advanced 3D tissue and disease modeling.

Learn about their insights into three reproducible and comprehensive 3D tissue models (intestine, vasculature, and liver) and their toxic responses to drug and inflammatory mediators using media sampling and imaging-based readouts.

Watch our on-demand webinar and hear our speakers Henriette Lanz, PhD (VP Biology at MIMETAS) and Dorota Kurek, PhD (Senior scientist at MIMETAS) discuss various topics.

Learn how the OrganoPlate® was used to model immune cell interaction in endothelial inflammation to establish a model ideal for routine target screening towards the treatment of chronic vascular inflammation.

Learn how we employed the OrganoPlate® platform in conjunction with the Tecan Spark® Cyto multimode plate reader in an assay to investigate the toxic effect of snake venom on endothelial tubules grown in the chip.

Immerse yourself in an overview of our 3D in vitro modeling capabilities of neurological diseases and delve deeper into an application of a robust, immune-competent BBB-on-a-chip model used to investigate neuroinflammation.

Learn how our developed model may be used for an array of applications, highlighting its unprecedented versatility and physiological relevance.

Learn about current methods used to study PDAC and highlight the advantages of Organ-on-a-Chip technology for modelling bio- and physicochemical features of the disease.

Watch our on-demand webinar and join us as we explore how Organ-on-a-Chip technology provides scientists with scaled-up and powerful new insights from relevant biological models and more accurate predictions on the safety and efficacy of investigational drugs in humans.

In this roundtable discussion, immuno-oncology decision-making experts from pharma, biotech, and academia discuss the complexity of cancer and its diagnosis.The panel also share their perspectives on current and future approaches towards cancer management and explore paradigm shifts surrounding immuno- and precision oncology.

In this roundtable discussion, a panel of experts from pharma, biotech, and academia discuss challenges in the diagnosis and treatment of IBD, sharing their perspectives on current approaches towards the disease, and consider paradigm shifts happening within IBD drug development.

Learn about our 3D BBB-on-a-Chip developed in the OrganoPlate®, that combines fast, high-throughput readouts with human-relevant conditions, revolutionizing the way scientists study the BBB.

Learn how to measure TEER in 3D in vitro tissue barrier models to assess barrier integrity and function in a high-throughput format.

Discover how we developed a fully polarized 3D in vitro renal proximal tubule model and further validated through drug-drug interaction studies focusing on two important efflux mechanisms in renal proximal tubules.

To advance drug discovery, more comprehensive 3D in vitro models are needed. Ones that go beyond the traditional compartmentalized setups and mimic different complex cell type interactions by modeling human microvasculature. We introduce OrganoAccess: a robust, self-organizing microvascular platform with gravity-driven unidirectional flow. A stable, scalable, and screening-ready model design integrates immune cells to probe immune responses across different conditions, while the longevity of the vascular bed enables both acute and chronic exposure studies of drug efficacy.

This application note showcases how the OrganoReady® Colon Organoid enables more predictive ADME/Tox testing by combining 3D human tissue architecture with dynamic flow. It supports accurate assessment of drug transport and metabolic activity beyond conventional in vitro models.

Cells in vivo experience a complex, three-dimensional environment that exposes them to circulating molecules, neighboring cells, and the extracellular matrix (ECM). Organ-on-a-Chip is a powerful technology driving human relevance by utilizing microfluidic techniques. Organ-on-a-Chip systems, such as the MIMETAS OrganoPlate® platform, aim to mimic cell-matrix and cell-cell interactions, and recreates human tissue microenvironment in vitro. Since most platform technologies are either based on single chips or small numbers of chips in dedicated surroundings, applications for Organ-on-a-chip are largely envisioned in pre-clinical testing. MIMETAS’ platform combines physiological relevance with scalability to enable the potential of automation, facilitating upscaling and streamlining research processes. In this white paper, we give a detailed report on a 1546 compound screen on a robust 3D angiogenic sprouting assay. Download the white paper to learn exactly how we combined the OrganoPlate® platform with an automated workflow to deploy it as a high-throughput screening tool. You will also explore how image-based phenotypic screening offers high-resolution information and generates selective hits and novel biological insights.

Cancer remains a formidable challenge worldwide, necessitating innovative solutions and the critical need for models that precisely mimic human responses, given the high failure rates in clinical trials. This whitepaper reveals how MIMETAS's pioneering organ-on-a-chip technology and 3D tissue modeling expertise represent a significant advancement in closing the translational gap in cancer drug discovery. MIMETAS' cancer modeling capabilities are showcased through six case studies, highlighting our ability to model processes such as immune cell migration, CAR T cell efficacy, and the TME's complex interactions, all contributing to drug discovery progress.

Developing effective therapies for immunological diseases remains a major challenge due to the complexity of the immune system and limitations in traditional preclinical models. Many promising drug candidates fail in clinical trials due to a lack of predictive accuracy in existing in vitro and in vivo models. This whitepaper examines how advanced 3D tissue models can improve translational relevance in immunology drug discovery, addressing key challenges in diseases such as inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Key Topics Covered: The biggest challenges in immunology drug discovery – and how to overcome them Breakthrough 3D tissue models for vascular inflammation, IBD, and CKD research Case studies showcasing real-world applications in immunology drug testing How advanced microphysioloigical systems improve therapeutic efficacy predictions How 3D human tissue models can enhance drug screening and mechanistic insights.

Drug-induced gastrointestinal (GI) adverse events are a major challenge in developing new therapeutics, particularly for oncology drugs targeting rapidly dividing cells. Current models often fail to accurately predict these toxic effects and lack translational value, emphasizing the need for more advanced 3D tissue models of the intestine.To fill this gap, MIMETAS developed the OrganoReady® Colon Organoid—a comprehensive and translatable 3D intestine model that combines the benefits of adult stem cell-derived organoids with the OrganoPlate® Organ-on-a-Chip platform. This model allows researchers to predict both on-target and off-target drug effects more effectively. This application note demonstrates how the OrganoReady Colon Organoid can be integrated into toxicology workflows to identify GI toxicity mechanisms using robust multiplex assays, including transepithelial electrical resistance (TEER), cell viability, cytotoxicity, and CYP3A4 activity. Benefits • Screenable ready-to-use 3D human colon organoid model • A translatable adult stem cell-derived solution (license included) • Validated for drug screening of gastrointestinal adverse effects• Apical and basolateral access enables the study of orally and intravenously administered drugs

A 3D perfused multicellular intestinal model: the intestine-on-a-chip system replicates key features of inflammatory bowel disease using perfused multicellular tubules and immune cell co-culture, enabling automated screening of anti-inflammatory drug candidates.

A physiologically relevant 3D migration model: The endothelium-on-a-chip system enables high-throughput analysis of T cell transendothelial migration in response to chemotactic and tumor-derived triggers using perfused vessels and standard lab equipment.

The OrganoPlate® 2-lane 96 is a microfluidic cell culture platform that enables culturing and screening of a range of miniaturized 3D organs and tissue models. Here we describe the development of a functional 3D liver-on-a-chip model on the OrganoPlate®. The 3-liver cell type model was constructed by seeding differentiated induced pluripotent stem-cell derived hepatocytes (iHeps) in collagen extracellular matrix in the top channel of the chip, and endothelial and Kupffer cells in the bottom channel. Characterization of the model showed that the culture achieved a mature hepatocyte phenotype over time. The model was capable of detecting known hepatotoxins and four robust assays were identified and used in a compound library screen of 159 compounds. Identified toxic hits were ranked in hepatotoxicity by a composite score and a follow-up dose-response assessment was conducted. The platform’s compatibility with standard laboratory equipment and automation makes this liver-on-a-chip model amenable to highthroughput screening. This physiologically relevant model enables hepatotoxicity testing and provides valuable insight into drug efficacy studies for liver diseases.

A high-throughput 3D angiogenesis model: The angiogenesis model enables automated, perfused culture of endothelial cells forming sprouts in response to angiogenic cues, supported by integrated robotics and imaging systems for efficient and scalable vascular biology research.

A high-throughput 3D model: This BBB-on-a-chip system uses perfused primary human brain microvascular endothelial cells to replicate barrier integrity, transporter function, and cytokine-induced disruption, enabling compound screening and mechanistic studies of the blood-brain barrier.

A perfused 3D immune model: The OrganoPlate® platform enables real-time analysis of T cell transendothelial migration under inflammatory conditions by integrating a vessel structure with extracellular matrix and high-content imaging for quantification.

Snakebites pose a significant global health threat, affecting millions and causing tens of thousands of fatalities annually. Many snake venoms disrupt blood vessels, leading to severe physiological consequences. To address the need for advanced in vitro models for snakebite research, we used OrganoReady Blood Vessel models to assess snake venom effects on human tissue. This method leverages 3D human blood vessels in a microfluidic system, the OrganoPlate®, enabling precise control over physiological parameters.